Ottawa, February 24, 2022—Innovative Medicines Canada is saddened and dismayed by Russia’s unprovoked invasion of Ukraine. These acts are in direct violation of Ukraine’s sovereignty, and we support efforts by Canada and its allies to bring an immediate resolution to this conflict. We extend our heartfelt sympathies and thoughts to all those affected by these tragic acts both at home, and abroad.
Industry’s response to the war in Ukraine
Following the invasion of Ukraine, the global pharmaceutical industry responded quickly by providing financial support and in-kind donations of medical supplies to NGOs to help ensure essential medicines and vaccines reach those who need them.
Contributions have been made through existing corporate foundations, employee-matching initiatives, and donations to global humanitarian relief organizations. Currently, IMC member companies’ combined global donation is ~$67 million CDN. Medicine and supply donations are also being made through Health Partners International Canada.
For an overview of global sector-wide contributions, please visit: EFPIA Pharmaceutical industry response to the war in Ukraine – the information on this page is updated regularly.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. “The association represents 50 companies who invest nearly $1.2-billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8-billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
– 30 –
For further information:
Director, Media Relations & Content
E-mail: [email protected]